capecitabine has been researched along with Carcinoma, Papillary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, R; Ansari, D; Kölby, D; Sasor, A; Thilén, J | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E | 1 |
| Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I | 1 |
| Bauer, A; Francis, GL; Helms, A; Patel, A; Pluim, T; Tuttle, RM | 1 |
1 review(s) available for capecitabine and Carcinoma, Papillary
| Article | Year |
|---|---|
Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms | 2015 |
1 trial(s) available for capecitabine and Carcinoma, Papillary
| Article | Year |
|---|---|
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Rate | 2012 |
3 other study(ies) available for capecitabine and Carcinoma, Papillary
| Article | Year |
|---|---|
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Papillary; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epothilones; Female; Fluorouracil; Follow-Up Studies; Humans; Long-Term Care; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2010 |
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Child; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Immunohistochemistry; Male; Thymidine Phosphorylase; Thymidylate Synthase; Thyroid Neoplasms | 2004 |